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Abstract
The metabolic syndrome is a condition characterized by a special constellation of reversible major risk factors for
cardiovascular disease and type 2 diabetes. The main, diagnostic, components are reduced HDL-cholesterol, raised
triglycerides, blood pressure and fasting plasma glucose, all of which are related to weight gain, specifically intra-
abdominal/ectopic fat accumulation and a large waist circumference. Using internationally adopted arbitrary cut-off
values for waist circumference, having metabolic syndrome doubles the risk of cardiovascular disease, but offers an
effective treatment approach through weight management. Metabolic syndrome now affects 30–40% of people by age 65,
driven mainly by adult weight gain, and by a genetic or epigenetic predisposition to intra-abdominal/ectopic fat accumu-
lation related to poor intra-uterine growth. Metabolic syndrome is also promoted by a lack of subcutaneous adipose
tissue, low skeletal muscle mass and anti-retroviral drugs. Reducing weight by 5–10%, by diet and exercise, with or
without, anti-obesity drugs, substantially lowers all metabolic syndrome components, and risk of type 2 diabetes and
cardiovascular disease. Other cardiovascular disease risk factors such as smoking should be corrected as a priority. Anti-
diabetic agents which improve insulin resistance and reduce blood pressure, lipids and weight should be preferred for
diabetic patients with metabolic syndrome. Bariatric surgery offers an alternative treatment for those with BMI 40 or
35–40 kg/m2 with other significant co-morbidity. The prevalence of the metabolic syndrome and cardiovascular disease is
expected to rise along with the global obesity epidemic: greater emphasis should be given to effective early weight-
management to reduce risk in pre-symptomatic individuals with large waists.
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Introduction
Individuals with cardiovascular disease (CVD) (coron-
ary heart disease (CHD) or cerebrovascular accident)
often have a constellation of aetiologically linked car-
diometabolic risk factors including dyslipidaemia, high
blood pressure and high fasting plasma glucose, which
may or may not co-exist with a number of inflamma-
tory markers (e.g. C-reactive protein, uric acid and
cytokines) and prothrombotic state (e.g. plasminogen
activator inhibitor-1).1 Reaven2 was the first to draw
attention to this clustering of metabolic abnormalities,
particularly in overweight individuals. He coined the
name ‘syndrome X’, however, this term is also used
by cardiologists to indicate angina-like chest pain in
association with reversible electrocardiographic signs
of myocardial ischaemia in the absence of flow-limiting
stenosis on coronary angiography,3 a condition also
more often found in obese individuals. Other terms
have been used previously in the literature such as insu-
lin resistance syndrome and plurimetabolic syndrome,
but ‘metabolic syndrome’ has gained international
acceptance and International Classification of
Diseases coding (E88.81) in the past two decades.
Arbitrary cut-offs based on epidemiological studies
have been adopted for waist circumference4 and for
the biochemical components.5,6 Recognizing the greater
risk of type 2 diabetes and premature CVD in
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overweight people of Asian origin, compared to those of
European origin, lower cut-off values are applied for
Asians. Some experts have been critical of the concept
of the metabolic syndrome, referring to the dominant
role waist circumference over the remaining components
of the syndrome such that, in its entirety, the metabolic
syndrome appears to add little improvement on waist
circumference alone on risk assessment or therapeutic
value.7 While there has been semantic debate as to
whether it should be considered a ‘syndrome’, metabolic
syndrome has shown extensively to promote the devel-
opment of diabetes and CVD8,9 and CVD related mor-
tality.9–12 The appearance of the metabolic syndrome
phenotype is provoked by weight gain, particularly an
increase in intra-abdominal fat accumulation which is
mirrored by a large waist circumference. The prevalence
of the metabolic syndrome and CVD is expected to rise
dramatically in parallel to the global obesity epidemic.
Metabolic syndrome doubles the risk of CVD but since
its components are all reversible, the diagnosis of meta-
bolic syndrome offers an effective treatment approach –
principally weight management.
Classification of body fat
and fat distribution
Guidelines for healthy weight have traditionally been
based on body mass index (BMI) cut-offs recom-
mended by the World Health Organization (WHO)
for use in epidemiology.13 More recently, waist circum-
ference ‘action levels’4 have been widely used both
in epidemiological studies and clinical assessments
(Table 1) and adopted by the National Cholesterol
Education Program (NCEP)5 and International
Diabetes Federation (IDF)6 as the focal component
of the metabolic syndrome.
It is important to point out that BMI is not a strong
predictor of body fat: in most studies which have mea-
sured estimated total body fat by a reference method
(underwater weighing, deuterium oxide dilution disper-
sal and magnetic resonance imaging), the amount of
variance (R2) in body fat explained by BMI is about
70–80% in adults.14,15 Waist circumference predicts
body fat similarly,15 but is a somewhat better guide to
cardiometabolic disease risks because it identifies
people with relatively low BMI but with increased
intra-abdominal fat accumulation.16 A more rational
approach to obesity would use the published, validated,
equations to estimate body fat from a combination of
anthropometric measurements.17 Similar equations are
available to estimate skeletal muscle mass, which is fun-
damental to metabolic risk status.18 All these methods
can be used to describe populations and groups, but
none is appropriate for classifying individuals.
Diagnostic criteria of metabolic syndrome
Diagnostic criteria have been variably defined by a
number of organizations including the WHO,
European Group for Study of Insulin Resistance,
NCEP, IDF and the American Association of Clinical
Endocrinologists.19 The most widely accepted criteria
for the metabolic syndrome are those adopted by the
NCEP5 and IDF,6 using waist circumference ‘action
levels’ which emerged from epidemiological analyses
and subsequently confirmed to reflect cardiometabolic
risks in many other studies of European-origin adults
(Table 2). The NCEP incorporated cut-offs of blood
pressure, high-density lipoprotein (HDL) cholesterol,
triglycerides and fasting plasma glucose set at levels
below their individual treatment thresholds but when
used in cluster greatly elevate the risks of premature
Table 1. Classification of body mass index and waist circumference and risk of obesity related co-
morbidities.
Body mass indexa
Men and women 18.5–24.9 kg/m2 25–29.9 kg/m2 30 kg/m2
Classification Normal weight Overweight Obese
Risk of co-morbidities Low Increased High
Waist circumferenceb
Men <94 cm 94–101.9 cm 102 cm
Women <80 cm 80–87.9 cm 88 cm
Classification Normal fat
distribution
Moderate central
fat accumulation
High central fat
accumulation
Risk of co-morbidities Low Increased High
aWHO.12
bLean et al.4
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CHD and of type 2 diabetes.5 These criteria also
included a large waist circumference and require the
presence of any three of the components for diagnosis.
The IDF proposed a simpler set of criteria requiring a
large waist circumference but set at a slightly lower
level than that of NCEP, plus any two of the other
components.6 The IDF criteria were produced to
incorporate prevention of diabetes, as well as CVD,
thus the lower cut-off ‘action levels’ of waist circumfer-
ence and fasting plasma glucose were employed. Aside
from their use in epidemiological surveys, the goal of
applying these diagnostic criteria is to initiate interven-
tions in the clinical setting for an individual’s weight
management, in order to prevent CVD and diabetes.
Aetiology
Development of metabolic syndrome depends on two
elements: firstly adult weight gain, with body fat accu-
mulation and secondly a predisposition to locate fat in
intra-abdominal sites, including ectopic fat in liver,
pancreas and heart.5,6
The metabolic syndrome is strongly linked to a life-
style characterized by an easy access to unlimited
supply of high caloric, low nutrient-dense, foods and
physical inactivity.20,21 This exposure is most potent
during early period of life resulting in childhood obesity
which is a major risk for metabolic syndrome in
adults.22 Psychosocial stress has also been suggested
to contribute, with most metabolic components are
more prevalent in socioeconomically deprived popula-
tions.23 Not all individuals go on to develop the meta-
bolic syndrome because of the high individual variation
and genetic/epigenetic factors for both the components
of the syndrome, for example insulin resistance and
dyslipidaemia24 and body composition25 and their
expression varies with changes in external environment.
It is estimated that genetic factors contribute about
30% of the observed variance in BMI but about 70%
of the variance in fat distribution that relates more to
the metabolic syndrome.25 The lifestyle factors that
increase intra-abdominal fat and metabolic risk factors
are weight gain, a diet high in saturated fat, smoking,
inactivity and excess alcohol intake.
Increasingly, new insights into genetic basis of obes-
ity have been gained from genome wide association
studies (GWAS). The first single nucleotide polymorph-
ism (SNP) associated with increased BMI was mapped
to a gene now known as FTO (fat mass and obesity
associated) in 2007.26,27 FTO gene acts by regulating
appetite and energy expenditure. Over 40 genetic vari-
ants since have been identified to associate with BMI,
fat distribution or risk of obesity and metabolic syn-
drome.28 Although only a small proportion of variance
in BMI (<2%) is observed to be attributable to
common allelic variants, these risk alleles make sub-
stantial contribution to obesity in a polygenic manner
such that people who carry a higher number of variants
(more than 10) will likely to gain extra weight than
those who carry only one or two variants.29
While certain excessively rare single gene mutations
(e.g. leptin deficiency, leptin-receptor defects) can cause
massive obesity, usually manifest in early childhood,30
genetic factors which affect BMI appear to contribute
little to the very substantial weight gain needed to gen-
erate obesity.
The predisposition to deposit excess body fat in
intra-abdominal and ectopic sites appears mainly to
be determined very early in life. Poor intra-uterine
growth is a recognized factor,31 suggesting an
Table 2. Criteria for diagnosis of the metabolic syndrome as defined by the NCEP5 and more recent
proposals from the IDF6.
Defining level
Risk factor
NCEP proposals:
any three features
IDF proposals: large waist
plus two other features
Large waist circumference
Men 102 cm (40 in) 94 cm (37 in)
Women 88 cm (35 in) 80 cm (32 in)
Raised triglycerides 1.7 mmol/L (150 mg/dL) 1.7 mmol/L (150 mg/dL)
Reduced HDL cholesterol
Men <1.03 mmol/L (40 mg/dL) <1.03 mmol/L (40 mg/dL)
Women <1.29 mmol/L (50 mg/dL) <1.29 mmol/L (50 mg/dL)
Raised blood pressure 130/85 mmHg 130/85 mmHg
Raised fasting plasma glucose 6.1 mmol/L (110 mg/dL) 5.6 mmol/L (100 mg/dL)
Note: All individual components are below treatment thresholds, but combined in the metabolic syndrome, coronary
heart disease risk is doubled. If body mass index 30 kg/m2 then assume waist circumference is above treatment level.
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epigenetic mechanism.32 There is scattered evidence for
other exposures during pregnancy or early infancy, for
example maternal smoking.33 Aside from certain drug
effects (e.g. antiretroviral agents promote central fat
accumulation, thiazolidinediones reduce it),34 there is
little evidence that any factors in later life can modify
fat distribution.
Pathophysiology
High plasma glucose and insulin resistance
Some of the links between components of the meta-
bolic syndrome relate to insulin resistance, although
about a third of patients with the metabolic syndrome
have normal insulin sensitivity.35 Insulin resistance
is characterized by a high plasma insulin concentra-
tion that fails to suppress plasma glucose normally.
The contributing factors are complex, a central fea-
ture is unresponsiveness to insulin at the cellular
level because of changes in receptor binding or post-
receptor mechanisms. Exposure to high free fatty
acid (FFA) concentrations is a common mediator
which is a consequence of an expanded intra-abdom-
inal fat mass.36 Insulin resistance varies between
organs (e.g. subcutaneous/white and intra-abdominal/
brown adipose tissues, muscle, liver, skin); this may
be important in the clinical manifestation of insu-
lin resistance, pancreatic b-cell dysfunction and
impaired insulin secretion. Insulin resistance is closely
related to impaired glucose tolerance, diabetes and
risk of CHD.37
High blood pressure and insulin resistance
Many hypertensive individuals have glucose intolerance
and hyperinsulinaemia.36 However, this association is
probably not causally linked since controlling hyperten-
sion neither improves glucose intolerance or hyperinsu-
linaemia38 and hypertension is not observed in patients
with insulinoma.39 On the other hand, obesity contrib-
utes to hypertension and hyperinsulinaemia, while
weight reduction usually improves both of these dis-
orders.40 Insulin resistance and hyperinsulinaemia
could directly cause hypertension via an increase in cat-
echolamine activity independent of plasma glucose con-
centration. Increased insulin concentration may also
acutely raise blood pressure through insulin-mediated
renal tubular reabsorption of sodium.36
Dyslipidaemia
High triglyceride and low HDL cholesterol levels are
core components of the metabolic syndrome.
Derangements of these components have been shown
to associate with elevated levels of plasma small dense
low-density lipoprotein (LDL) cholesterol, the most
atherogenic subfraction of LDL, in individuals who
are susceptible to gain weight.41 Individuals with high
concentrations of these particles are at increased risk of
CVD.41,42
Large waist circumference and intra-abdominal
fat accumulation
Increased intra-abdominal fat accumulation, indicated
by a large waist circumference, may have a direct inter-
mediary role in the development of the metabolic syn-
drome.43 It is thought that the large amounts of FFAs
released by the metabolically active intra-abdominal fat
mass, via the portal system into the liver, may interfere
with hepatic insulin clearance.44 Intra-abdominal fat
which has its origin as brown adipose tissue (mainly
omental and retroperitoneal), exhibits greater mito-
chondrial density and rates of lipolysis and glycolysis
than the subcutaneous white adipose tissue.45 Intra-
abdominal fat appears to be primarily involved in
high-turnover distribution of FFAs to other body
organs. Metabolic complications arise when intra-
abdominal fat evolves into a fat storage. Intra-
abdominal adipose tissue is an active endocrine organ
secreting a range of adipocytokines including leptin,
adiponectin, resistin, interleukins (IL) such as IL-1
and IL-6, and tumour necrosis factor alpha (TNF-a),1
which are important factors in energy regulation. The
imbalanced release of these factors by an expanded
intra-abdominal fat mass is associated with increased
metabolic disorders.
Conditions associated with increased metabolic
syndrome and CVD
A number of conditions have been shown to associate
with increased risk of obesity, metabolic disorders and
CVD that may give clues to underlying pathophysi-
ology of the metabolic syndrome. Individuals with par-
tial lipodystrophy have rare loss-of-function mutations
of the PPAR gene, resulting in subcutaneous adipose
tissue atrophy. Such patients have a high incidence of
severe insulin resistance, diabetes, dyslipidaemia, hep-
atic steatosis and polycystic ovary syndrome in
females46 which are mostly reversed by treatment with
leptin.47 By contrast, individuals with acquired partial
lipodystrophy (as the result of persistent complement
activation) have intact PPARg and treatment with the
PPARg agonist rosiglitazone increases subcutaneous
adipose tissue through adipocyte proliferation.48 In
patients with spinal cord injury, extreme disuse and
consequent muscle atrophy and altered muscle fibre
characteristics and function (oxidative and anaerobic
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capacity) is associated with increased central fat distri-
bution and metabolic disorders.49 Observations of high
incidence of the metabolic syndrome in individuals with
partial lipodystrophy or those with spinal cord injury
have highlighted the important roles of subcutaneous
adipose tissue and skeletal muscle in the development
of metabolic disturbances. Lifelong exposure to gluco-
corticoids, such as in patients with congenital adrenal
hyperplasia to control hyperandrogenism is linked to
excess risk of obesity and metabolic disorders.50,51 In
cancer survivors, who are known to have increased risk
of CVD, excess rates of obesity and metabolic disorders
have been observed which are thought to be the conse-
quence of late effects of chemotherapy and radiother-
apy.52 Low birthweight, a marker of poor early growth,
is strikingly associated with metabolic disorders in
adult life. Using the thrifty and programming hypoth-
eses, Barker suggested that poor nutrition in utero and
early life has an adverse effect on the structure and
function of vital organs.53 Since the endocrine and car-
diovascular systems develop late in the foetus, they are
more severely affected by undernutrition in the later
trimesters. Such individuals would stay unaffected if
they remained in an environment of reduced nourish-
ment, but suffer health problems when exposed to cer-
tain stimuli such as abundant food, corticosteroids or
stress. The time of onset and severity of the disease in
adult life is determined by obesity and physical inactiv-
ity. These hypotheses help explain, in part, the high
incidence of obesity, metabolic syndrome, type 2 dia-
betes and CHD observed in immigrants from the
Indian sub-continent to Western countries. There is evi-
dence that increased central body fat distribution, com-
monly observed in migrant South Asians compared
with general white British, diminished in the next gen-
eration of British-born South Asians, at least in
females.54 However, the persistent greater risk of dia-
betes and hypertension in African Americans55 and
CHD in South Asians56 who were born in the West
compared with white Caucasians suggest other factors,
driven by genetic and/or epigenetic processes, are
involved to promote body fat and lean body mass
development, and more crucially body fat distribution
and the less studied muscle fibre composition with are
known to have significant impact on insulin sensitivity.
There is evidence from various studies to support this
notion. A study by Nightingale et al.57 has suggested
that the metabolic sensitivity to adiposity was greater in
South Asian children than white European children,
while another study has shown that African American
women had increased proportions of the less oxidative
and more insulin resistant type IIB muscle fibres than
white women.58 These findings are in line with another
small study of 20 British South Asians and 20 white
British men of similar BMI, showing South Asian
men had reduced insulin sensitivity, exercise capacity
and skeletal muscle expression of key insulin signalling
proteins.59
Implications of metabolic syndrome
prevalence on CVD
The prevalence of metabolic syndrome is estimated to
be between 10 and 30%, increasing sharply in older
age-groups in most European countries.60 Data from
the National Health and Nutrition Examination
Survey showed that the prevalence of metabolic syn-
drome in the United States was 28% in the 1988–
1994 survey and had risen to 34% in the 1999–2004
survey.61 By the age of 70, the prevalence of metabolic
syndrome rose to 42% among American men and
women.62
It is likely that the prevalence of metabolic syndrome
will continue to rise in the future given the persistently
rising trends in obesity, especially among young people.
The epidemic of obesity and metabolic syndrome will
have major impact on the future risk of CVD, both
short term (10-year risk) and long term (lifetime). As
population age, and inactivity and overweight become
the norm, world-wide, it is likely that metabolic syn-
drome will become more frequent in older people.
Sarcopenic obesity has yet to be defined in a way that
can be used for clinical diagnosis or even for an agreed
assessment of survey data, but studies using birth
cohorts have shown a disconnect between changes in
BMI and waist circumference in older people, with
waists continuing to rise even when BMI has plat-
eaued;63 this implies loss of muscle while fat is still
rising: a recipe for metabolic syndrome.
In order to prevent or reduce long-term risk for
CVD, preventative interventions should be initiated
for individuals diagnosed with the metabolic syndrome,
with a focus on weight management to reduce excessive
central fat accumulation. Starting treatment solely on
the basis of large waist is perfectly reasonable, without
waiting for other components to develop. Risk assess-
ment for CVD should incorporate the identification of
metabolic syndrome along with other cardiometabolic
risk factors (Table 3) especially when estimating short
term CHD risk (e.g. 10-year risk). By assessing the
metabolic syndrome in conjunction with the
Framingham risk score, the severity of CHD could be
estimated for individuals with additional risk factors.
The NCEP suggested categorizing these individuals
according to absolute 10-year risk, with very high-risk
category comprising those with existing CVD or with
type 2 diabetes (diabetes is classified as a CHD risk
equivalent) irrespective of the presence or absence of
other risk factors. For those with metabolic syndrome
without CVD or type 2 diabetes, three ‘risk categories’
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are established in conjunction with the Framingham
risk score to estimate 10-year risk for CHD (Table 3).5
These ‘risk categories’ valuably provide an indication for
intensity of treatment of the individuals.
Medical management
Management goal of the metabolic syndrome focuses
on lifestyle changes such daily intake of five portions of
fruit and vegetables64 and reduction in regular alcohol
consumption to reverse modifiable risk factors for ath-
erosclerotic disease and to prevent health complications
including liver disease and cancer65 (Table 4). Since
weight management has multiple clinical and personal
benefits, with no appreciable hazards, there is an argu-
ment for offering evidence-based weight management
to all patients with large waists, irrespective of the
other components. A new proposed management-direc-
ted algorithm is shown in Table 5.66,67 People with BMI
in the upper end of the normal range are at substantial
increase in the risk of the metabolic syndrome.
Maintaining BMI at 21–22 kg/m2 is optimal for those
at risk for genetic or for other reasons such as preven-
tion of type 2 diabetes. However, a quite modest weight
loss of 5–10% has been shown to substantially benefit
in all metabolic risk factors for overweight individuals.
Modest lifestyle interventions are also effective in redu-
cing the risk of developing diabetes in individuals with
glucose intolerance.68,69 The composition of macronu-
trients has been shown to similarly benefit risk reduc-
tion. A recent meta-analysis of 19 randomized
controlled trial (n¼ 3209) of a minimum of 12 weeks
follow-up has shown no differences in metabolic out-
comes from weight loss with low-carbohydrate com-
pared with higher-carbohydrate/balanced diets for
type 2 diabetes or non-diabetic subjects.70 Similar find-
ings were observed in another meta-analysis of nine
studies (n¼ 1161) in those who were exposed to either
low-carbohydrate or low-fat diets.71 Physical activity
has benefits above its role in weight control by reducing
the risk of developing metabolic syndrome.72 In indi-
viduals with type 2 diabetes whose risk for CVD is
accentuated, more intensive risk factor management is
warranted. In the case of cardiometabolic risk-asso-
ciated drug therapy for conditions such as congenital
adrenal hyperplasia50,51 and cancer,52 increased moni-
toring and early interventions are required to limit the
long-term adverse effects of the treatment.
Drug therapy is directed towards the major risk fac-
tors. A number of drugs have been shown to improve
more than one metabolic syndrome component and
may shed lights to the underling biochemical disorders.
The PPARg agonists thiazolidinediones act by shifting
intra-abdominal fat to subcutaneous fat depot34 with
an associated improvement in glucose tolerance and
lipid profile. The expanded mass of metabolically
favourable subcutaneous adipose tissue appears to
serve as a sump for glucose and lipid disposal.
Biguanides, used to treat type 2 diabetes, have also
been shown to improve lipid profile and regulate men-
strual cycles and increase fertility in patients with poly-
cystic ovary syndrome. However, biguanides have not
been shown to modify all components of the metabolic
syndrome and not known to alter body fat distribution.
Treatment with anti-obesity drugs such as tetrahy-
drolipstatin (e.g. orlistat)73 and serotonin–noradren-
aline reuptake inhibitors (e.g. sibutramine – note: this
drug has been withdrawn from some countries)74 leads
to weight loss and, more importantly, reduction in
long-term weight regain. These drugs have been
shown to reverse or delay most components of the
metabolic syndrome. Orlistat has been shown to
reduce the incidence of metabolic syndrome and of dia-
betes by 30–40%75 and sibutramine is expected to have
similar properties, but their effects on CHD are
unknown. One of the adverse effects of orlistat is the
Table 3. Risk categories suggested by NCEP based on the individual’s risk status.
CVD or type 2 diabetes
Metabolic syndrome without
CVD or type 2 diabetes
Framingham 10-year risk for CHDa CHD risk equivalentb >20%c 10–20% <10%
Risk category Very high High Moderately high Low to moderate
Note: Type 2 diabetes is considered as a CHD risk equivalent. A CHD risk equivalent is a condition that carries an absolute risk for developing new
CHD equal to the risk for having recurrent CHD events in persons with established CHD. The presence of CHD or type 2 diabetes places the
individual in the very high risk category irrespective of the presence or absence of other risk factors. The severity of individuals with metabolic
syndrome but without CVD or type 2 diabetes are based on the Framingham 10-year risk for CHD calculated from their other risk factors.
aRisk factors included for calculating the Framingham of 10-year risk for CHD are age, total and HDL cholesterol, systolic blood pressure, treatment
for hypertension and cigarette smoking (refer to NCEP5 for risk calculation tables).
bThe presence of CHD or type 2 diabetes places the individual in the ‘very high risk’ category irrespective of the presence or absence of other risk
factors. Other CHD risk equivalents include individuals with peripheral arterial disease, abdominal aortic aneurysm, carotid artery disease (symp-
tomatic, e.g. transient ischemic attack or stroke of carotid origin or >50% stenosis on angiography or ultrasound), and other forms of clinical
atherosclerotic disease, e.g. renal artery disease).
cThis category is also considered as a CHD risk equivalent.
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unpleasant and often intolerable loose bowel move-
ments which increase more frequently with greater fat
ingestion. Serotoninergic agents may have independent
effects on blood pressure and glucose tolerance, but do
not have identical actions; sibutramine tends to raise
blood pressure unless this is counteracted by the
blood pressure reduction that occurs with weight loss,
while fluoxetine has a minimal effect on appetite.
Although sibutramine treatment is contra-indicated in
individuals with high cardiovascular risk factors, the
Sibutramine Cardiovascular Outcome Trial (SCOUT)
has shown that sibutramine treatment with weight
management is well tolerated by the majority of high-
risk individuals with CVD.76
Two classes of insulin secretagogues are currently
in use for treating patients with type 2 diabetes who
have sufficient b-cell reserve. The oral agents dipeptidyl
peptidase-4 (DPP-4) inhibitors act by increasing
endogenous activity of glucagon like peptide-1
(GLP-1) while the injectable GLP-1 receptor
Table 4. Management of the metabolic syndrome through lifestyle changes and drugs to reverse modifiable risk factors for ath-
erosclerotic disease.
Daily core foods Weekly core foods
 Five or more portions of fruit or vegetables64
 1–2 servings of pulses, fish, meat (in reducing order
of helping-size and weekly frequency)
 Two cup-sized helpings of potatoes, pasta or rice
 One glass of low-fat milk
 Bread: six slices for men, five slices for women
 One bowl of cereal with low-fat milk
 Alcohol: maximum 14 units a week for men and womena
 5–7 servings of pulses (beans, chick-peas, lentils)
 Two portions of fish or fish products
 Two servings of cheese (more if no meat)
 Three portions of meat: (avoid processed meat)
 Limit butter and margarine (maximum 85–110 g)
 Weekly alcohol limit men: 21  10 gram units,
women 14 units
Smoking cessation
 Advice and support for cessation, including drugs
Minimize physical inactivity
Drugs Restrict television viewing/computer use, avoid motor
transport for short journeys, activity-oriented
holidays and leisure time.
 Biguanides (e.g. metformin)
 PPARg agonists (e.g. pioglitazone)
 DPP-4 inhibitors (e.g. linagliptin)
 GLP-1R agonists (e.g. liraglutide, exenatide)
 Tetrahydrolipstatin (e.g. orlistat)
 Serotonin–noradrenaline agonists/reuptake inhibitors
(e.g. sibutramine, lorcaserin)
Increase daily moderate exercise
 Active travel, active leisure, regular swimming,
climbing stairs, brisk walking, dancing, household activities
 Monitor step-counts and set weekly targets,
aiming to reach an average 10-15,000 steps/day
aTo avoid chronic heavy drinking and binge-drinking leading to increased health risks such as liver disease and cancers, the UK Departments of Health have
made new recommendations, setting the limit of alcohol intake to a maximum of 14 units per week (the equivalent of seven glasses of wine and six pints of
beer) for men and women, and to include at least two alcohol-free days a week. Women should avoid alcohol intake completely during pregnancy.65
Table 5. Pragmatic suggestions for the management of elevated waist circumference in relation to CVD risk
(adapted from Lawlor et al.66).
Waist circumference 10-year CVD riska Level of risk Intervention
Men: <94 cm Low Avoid weight gain and stay below these levels
Women: <80 cm
Men: 94 cm <10% Elevated Requires public health measures to check
and prevent continued weight gain
Women: 80 cm
Men: 94–101.9 cm >10% High Requires effective treatment to lose 5–10% body weight
and prevent further weight gain
Women: 80-87.9 cm
Men: 102 cm Irrespective of risk High Requires effective treatment to lose >10% body weight
and prevent further weight gain
Women: 88 cm
aCVD risk based on Joint British Societies’ guideline or equivalent.67
Han and Lean 7
(GLP-1R) agonists directly activate GLP-1R expressed
in the pancreatic b-cells, leading to enhanced insulin
synthesis and secretion in the presence of elevated
plasma glucose.77 GLP-1R agonists have also been
shown to suppress the secretion of glucagon. Since
GLP-1 receptors are expressed in a wide range of
extra-pancreatic organs, including the gastrointestinal
tract and the brain, GLP-1R agonists have major
effects on the gut–brain axis by delaying gastric empty-
ing and promoting hypothalamic satiety, resulting in
weight loss78 and reduction in hepatic fat content, but
the evidence of their long-term effects on metabolic dis-
turbances is not yet available. A few studies of small
samples and short term duration of treatment with
DPP-4 inhibitors have shown conflicting results79
while Boschmann et al.80 found no changes in a
number of risk factors.
One of the recently approved anti-obesity drugs by
Food and Drug Administration and European
Medicines Agency is the combination of bupropion
and naltrexone (approved name Contrave in the
United States and Mysimba in Europe). Bupropion,
usually used as treatment for depression and smoking
cessation, is an aminoketone acting as a mixed dopa-
mine/norepinephrine reuptake inhibitor.81 Naltrexone,
used as treatment for alcohol dependence, is an opioid
receptor antagonist which reduces cravings by inhibit-
ing the action of b-endorphins on dopaminergic reward
pathways.82 Treatment with the combination of sus-
tained-release naltrexone (32mg/day) and bupropion
(360mg/day) over 56 weeks has been shown to reduce
body weight by 6.1 kg (equivalent to 6.1%).83
In general, weight loss through diet and lifestyle plus
anti-obesity drugs results in improvement in all the car-
diovascular risk factors of metabolic syndrome. Some
drugs, through their mode of action, have weight-inde-
pendent actions to enhance the benefit of weight loss
(e.g. orlistat on lipid-lowering, liraglutide on blood
pressure and glucose-lowering). In some cases, drug
affects may attenuate slightly the cardiovascular benefit
of weight loss (e.g. weight loss with Contrave/
Mysimba, or with sibutramine, reduces blood pressure,
but to a lesser degree than for the same amount of
weight loss if that can be achieved without the drug).
Surgical management
Medical treatment of obesity remains ineffective, par-
ticularly long-term weight loss, for a large number of
people even when intensive lifestyle modification com-
bined with the limited available pharmacological agents.
Bariatric surgery offers an alternative, but it has never
been shown that bariatric surgery works well in people
who have failed with a formal drug and diet approach.
People who fail with one approach tend to fail with
others. The National Institute for Health and Clinical
Excellence has made clear guidelines for individuals
who should be considered for bariatric surgery,84 to
reduce intake or absorption of calories. Various surgical
procedures are now available including gastric banding,
sleeve gastrectomy and gastric bypass. Criteria for bar-
iatric surgery require a BMI of above 40 or 35–40 kg/m2
with other significant co-morbidity (e.g. sleep apnoea,
type 2 diabetes or hypertension) that could be improved
by weight loss. The individual is usually required to have
exhaustively undertaken appropriate non-surgical
approaches, but failed to achieve clinically beneficial
weight loss for at least six months, to be fit for anaes-
thesia and surgery, and to commit to the need for long-
term follow-up. All bariatric surgical procedures have
potential complications, therefore should be performed
in a specialist centre.
Demand for gastric bypass surgery under the UK
National Health Service has risen by six-fold (from
808 to 5407 cases) in the five-year period between
2006–2007 and 2011–2012.85 Similar patterns have
been observed in the United States.86 In the current
frenzy to escalate bariatric surgery, it may be prudent
to step back and reflect on the ultimate goal of manage-
ment. The greater, more rapid weight losses by surgery
are off-set by a number of permanently social and health
consequences that the individual has to adapt, including
interference with daily activities such as the impossibility
of eating normal family meals and the hazards of dump-
ing syndrome, and of micronutrient deficiencies,
coupled with the need for revisionary surgery in 10–
20% of cases.87 It is important therefore optimized
non-surgical approaches should be offered readily for
obese individuals.88 If the aim is a more modest main-
tained weight loss of 15 kg (adequate to reverse type 2
diabetes) is the target, then low-energy liquid diet meth-
ods may be cheaper and safer than surgical option.89
Table 6 shows effects of weight loss on risk factors of
metabolic syndrome, in selected studies using various
regimens of low calorie diet, exercise, medications (orli-
stat or liraglutide) and bariatric surgery.75,90–96 As
expected, surgery results in greatest amounts of weight
loss and improvement in risk factors. Although low or
very low calorie diet does not lead to the same amounts
of weight loss but very calorie diet leads to the same
degree of risk reduction. The amounts of weight loss
or waist circumference reduction and improvement in
blood pressure by low calorie diet90,91 appear to be at
least as effective as treatment by drugs such as orlistat or
liraglutide.78 A study by Didangelos et al.75 has shown
that although the addition of orlistat to moderate calorie
restriction (1300kg/day) further reduced body weight by
only another 1.7 kg (1.5%), this treatment led to a dras-
tic reduction in fasting blood glucose (25%) that is usu-
ally observed in bariatric bypass surgery.
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Prevention
It is likely that risk factors exist long before overt symp-
toms of the metabolic syndrome and CVD are
expressed. Some individuals carry their risk from an
early age because of childhood obesity while others
endured even longer period due to their intra-uterine
growth retardation. A greater emphasis should be given
to risk prevention of pre-symptomatic individuals. At-
risk individuals can be screened from their family his-
tory. Regular physical activity and modest weight loss
is likely to prevent most features of metabolic syndrome
and, can even reverse all its components in those with
the existing syndrome, thereby reducing its prevalence
and incidence, as well as preventing new cases of dia-
betes. Smoking cessation is highly important not only
to the individuals, but also to their offspring to avoid
intra-uterine growth retardation and adverse epigenetic
modification leading to adult obesity. Anti-obesity
drugs or other agents such as PPARg agonists and
GLP-1R agonists may also be considered as primary
prevention of metabolic syndrome and CVD.
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